Indoco Remedies launches FEVINDO : 400 mg Favipiravir


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ indoco-remedies-launches-favipiravir-fevindo-400-mg
Now Indoco joins Favipiravir production with 400mg tablets

(Favipiravir) 400 mg Tablets in India. Fevindo - 400 (Favipiravir) is an antiviral drug, effective against the RNA-based influenza virus. The drug has been approved by DCGI in the treatment of Covid-19. Fevindo 400 reduces pill burden by 50% and ensures convenient dosing and better patient compliance.

Ms. Aditi Kare Panandikar, Managing Director - Indoco Remedies Ltd. commented, “The Covid-19 crisis has created a vast disruption to life in India and all over the globe. As part of the pharma industry, we have been able to do our bit in the prevention of Covid-19 with our brands Karvol Plus, ATM, Febrex Plus and Rexidin SRS Mouthwash. With the launch of FEVINDO, we are taking the next step from prevention to the treatment of Covid-19.”

Fevindo - 400 (Favipiravir) will be made available at all government approved COVID care centres and selected medical practitioners across the country. In addition to Fevindo, Indoco has two more new products for launch in Covid Care range, i.e., Povidone Iodine Gargle and Immunity booster chewable tablets with Zinc, Vitamin C and Vitamin D. Indoco has always been committed to providing quality medicines at affordable prices and with the launch of these products, the Company is all set to venture into the treatment of Covid-19.

Indoco Remedies Ltd., headquartered in Mumbai, is a fully integrated, research-oriented pharma company with presence in 55 countries. Indoco, a USD 145 million Company, employs over 5500 people including more than 300 skilled scientists. The Company has 9 manufacturing facilities, 6 of which are for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by most of the Regulatory Authorities including USFDA and UK-MHRA. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 70 million prescriptions annually from over 3,00,000 doctors belonging to various specialities.

Indoco has 9 domestic marketing divisions with a strong brand portfolio in various therapeutic segments including Respiratory, Anti-Infective, Dental Care, Pain Management, Gastro-intestinal,

Tags : #IndocoRemedies #FavipiravirLaunch #IndocoFavipiravir #FevindoFavipiravir #latestFavipiravirNewsSep28 #latestPharmaNewsSep28

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

University of Birmingham Dubai invites applications for MSc in Financial Data ScienceJuly 08, 2025
Benefits of ShirodharaJuly 07, 2025
WIKA India Launches “Re-Inventing Hygiene” Campaign to Advance Standards in Food & Pharma InstrumentationJuly 07, 2025
Cambodia is 2nd Asian country to rollout long-acting injectable HIV prevention optionJuly 07, 2025
Wheels of Care: How Tele-MRVs Are Reaching Mothers Left BehindJuly 07, 2025
Personalized Psychiatry's Developing Use of PharmacogenomicsJuly 07, 2025
Honourable Ministers Shri Anil Kumar Bachoo and Shri Palanivel Thiaga Rajan Open IIRSI 2025 Convention on Intraocular Implant & Refractive SurgeryJuly 05, 2025
A 69-year-old retired teacher gives a lesson of life by donating multiple organsJuly 05, 2025
Silent Scans, Smarter Eyes: Inside India’s First AI Teleradiology HubsJuly 05, 2025
Can You Hear Me Now? The Quiet Revolution of Tele-Audiology in Rural Childhood CareJuly 05, 2025
What’s on Their Plate? Uncovering Malnutrition Through Midday Meal DataJuly 05, 2025
Can Diabetics Conquer Space? The Mission That’s Changing Medicine on Earth and BeyondJuly 05, 2025
Center for Diagnostics and Telemedicine Celebrates Graduation of First Masters in Medical Artificial IntelligenceJuly 04, 2025
Sightsavers India Fellowship Programme Invites Applications for 2025July 04, 2025
After 4 Surgeries & 15kg Abdominal Tumour, 61-YO Reclaims Life In Marathon Operation At HCGMCCJuly 04, 2025
The DNA Warning: Are Genomic Screening Camps the Early Alarm We Need?July 04, 2025
Ticked, Tapped, and Forgotten? The Truth About Digital Consent FormsJuly 04, 2025
Evaluating the Impact of AI Chatbots in Mental Health Support for College StudentsJuly 04, 2025
Integrating Oral Health with Primary Care: Pilot Programs in Rural MaharashtraJuly 04, 2025
Will governments firewall public health from tobacco industry's lies and deceptive tactics?July 03, 2025